Drs Alex Spira and Dr Joshua Sabari discuss the results of the phase 1 CHRYSALIS study presented at ESMO 2020.
This study looked at amivantamab, an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor, in advanced EGFR positive NSCLC.
They cover the background to the study, look at the the efficacy and toxicity profiles for this combination therapy, and then discuss how this might affect clinician's choices and patient treatment journeys.
They finish by discussing other novel combinations and molecules being investigated in this area.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).